Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Graft vs Host Disease 2Colitis 2Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Crohn Disease 1Colitis, Ulcerative 1

Interventions

Infliximab 6etrolizumab 5Adalimumab 4golimumab 3Nivolumab 3CT-P13 3Specimen Handling 2Educational Status 2Colonoscopy 2vedolizumab 1pembrolizumab 1peficitinib 1cabozantinib 1Vitamin E 1Sutures 1Surgical Instruments 1Standard of Care 1Ringer's Lactate 1Proctocolectomy, Restorative 1Proctectomy 1Practice Guidelines as Topic 1Pneumococcal Vaccines 1Platinum Compounds 1Papillomavirus Vaccines 1Narrow Band Imaging 1NX-13 1Methylprednisolone 1Methods 1Mesalamine 1Medical Marijuana 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colitis, Ulcerative × vedolizumab × Clear all
NCT03802214 2020-12-21

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF(Tumor Necrosis Factor)Therapy

Stanford University

Terminated
1 enrolled

Colitis, Ulcerative

Data powered by HemOnc (CC BY 4.0) Colophon ⚡